Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

ALICIA (Observational Prospective Study of Acalabrutinib in CLL Therapy in Real Clinical Practice in Russia)

NCT04746950 is registered in ClinicalTrials.gov with AstraZeneca as lead sponsor.

NCT NCT04746950
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04746950 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
ALICIA (Observational Prospective Study of Acalabrutinib in CLL Therapy in Real Clinical Practice in Russia)
Lead sponsor
AstraZeneca
Phase
Observational
Overall status
Completed
Start date
February 3, 2021
Completion date
February 28, 2026
Enrollment
90 (actual)
Sites
15

Conditions

As the registry lists them; a condition with its own page is linked.

chronic lymphocytic leukemia